Milestone Pharmaceuticals Inc.
NASDAQ:MIST
2.03 (USD) • At close March 13, 2025
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Omzet
| 0 | 1 | 5 | 15 | 0 | 0 | 0 | 0 |
| Kosten van de omzet
| 0 | 0 | 0.48 | 0 | 0.376 | 0.236 | 0.01 | 0.008 |
| Brutowinst
| 0 | 1 | 4.52 | 15 | -0.376 | -0.236 | -0.01 | -0.008 |
| Brutowinstmarge
| 0 | 1 | 0.904 | 1 | 0 | 0 | 0 | 0 |
| Onderzoek- en ontwikkelingskosten
| 14.357 | 31.052 | 39.829 | 38.671 | 34.488 | 41.985 | 16.849 | 5.636 |
| Algemene en administratieve kosten
| 16.742 | 15.932 | 15.718 | 12.399 | 10.285 | 7.004 | 3.052 | 1.502 |
| Verkoop- en marketingkosten
| 0 | 15.114 | 9.095 | 7.003 | 5.937 | 8.892 | 3.921 | 1.13 |
| Verkoop-, algemene en administratieve kosten
| 16.742 | 31.046 | 24.813 | 19.402 | 16.222 | 15.896 | 6.973 | 2.632 |
| Overige kosten
| 0 | 0 | 0 | 7.003 | 0 | 0 | 0 | 0 |
| Bedrijfskosten
| 31.099 | 62.098 | 64.642 | 58.073 | 50.71 | 57.881 | 23.822 | 8.268 |
| Bedrijfsresultaat
| -42.102 | -61.098 | -59.642 | -43.073 | -50.71 | -57.881 | -23.822 | -8.268 |
| Bedrijfsresultaat ratio
| 0 | -61.098 | -11.928 | -2.872 | 0 | 0 | 0 | 0 |
| Totaal overige inkomsten en kosten netto
| 0 | 1.413 | 1.254 | 0.22 | 0.726 | 2.596 | 0.711 | 0.186 |
| Inkomen voor belasting
| 0 | -59.685 | -58.388 | -42.853 | -49.984 | -55.285 | -23.111 | -8.082 |
| Inkomen voor belasting ratio
| 0 | -59.685 | -11.678 | -2.857 | 0 | 0 | 0 | 0 |
| Belastingkosten
| 0 | 0 | -1.254 | -0.22 | -0.017 | -0.056 | 0.074 | 0.004 |
| Nettowinst
| 0 | -59.685 | -57.134 | -42.633 | -49.967 | -55.229 | -23.185 | -8.086 |
| Nettowinstmarge
| 0 | -59.685 | -11.427 | -2.842 | 0 | 0 | 0 | 0 |
| WPA (Winst Per Aandeel)
| -0.67 | -1.39 | -1.35 | -1.02 | -1.7 | -3.5 | -0.98 | -0.34 |
| Verwaterde WPA
| -0.67 | -1.39 | -1.35 | -1.02 | -1.7 | -3.5 | -0.98 | -0.34 |
| EBITDA
| -42.102 | -56.845 | -58.364 | -42.98 | -50.71 | -57.881 | -23.358 | -8.26 |
| EBITDA ratio
| 0 | -56.845 | -11.928 | -2.865 | 0 | 0 | 0 | 0 |